Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.
P Hwu, GE Shafer, J Treisman, DG Schindler… - The Journal of …, 1993 - rupress.org
The Journal of experimental medicine, 1993•rupress.org
To expand the spectrum of recognition of effector lymphocytes and to redirect them towards
predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes
(TIL) through stable modification with chimeric receptor genes consisting of single-chain
antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)
G and IgE Fc receptors. Using either hapten or ovarian carcinoma-specific monoclonal
antibodies, we constructed chimeric receptor genes and retrovirally introduced them into …
predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes
(TIL) through stable modification with chimeric receptor genes consisting of single-chain
antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)
G and IgE Fc receptors. Using either hapten or ovarian carcinoma-specific monoclonal
antibodies, we constructed chimeric receptor genes and retrovirally introduced them into …
To expand the spectrum of recognition of effector lymphocytes and to redirect them towards predefined targets, we have altered the specificity of human tumor-infiltrating lymphocytes (TIL) through stable modification with chimeric receptor genes consisting of single-chain antibody variable regions linked to the gamma subunit common to the immunoglobulin (Ig)G and IgE Fc receptors. Using either hapten or ovarian carcinoma-specific monoclonal antibodies, we constructed chimeric receptor genes and retrovirally introduced them into CD8+ TIL. Redirected TIL specifically lysed trinitrophenyl-labeled Daudi or a human ovarian carcinoma cell line (IGROV-1), and secreted granulocyte/macrophage colony-stimulating factor upon stimulation with the appropriate antigen. This strategy may allow new approaches towards the adoptive immunotherapy of cancer in humans.
rupress.org
